-+ 0.00%
-+ 0.00%
-+ 0.00%
Bristol Myers Squibb to Present Phase 3 Zenbexus Multiple Myeloma Data at ASH 2026
Share
Listen to the news
Bristol Myers Squibb to Present Phase 3 Zenbexus Multiple Myeloma Data at ASH 2026
  • Bristol Myers Squibb will present hematology trial data at the ASH meeting in New Orleans, December 12-15, 2026.
  • Phase 3 EXCALIBER-RRMM results will assess disease progression and residual disease with a Zenbexus-based combination in relapsed or refractory multiple myeloma.
  • Five-year Phase 3 TRANSFORM follow-up will highlight Breyanzi's potential for cure in second-line relapsed or refractory large B-cell lymphoma.
  • Early-stage results will evaluate dual-targeted CAR T therapy tunlucabtagene autoleucel's safety and efficacy in relapsed or refractory multiple myeloma.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bristol-Myers Squibb Company published the original content used to generate this news brief via Business Wire (Ref. ID: 20261118967070) on November 19, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending